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Abstract: The main treatment for pterygium is surgical removal. However, pterygium surgery 
is concerned with high rates of postoperative recurrence. Predicting factors of recurrence are 
not fully understood, yet, but they probably depend on a multitude of patient-related, clinical, 
and/or surgical factors. Several adjuvant treatments have been proposed to reduce postoperative 
pterygium recurrence, including different antimetabolites, antiangiogenetic factors, and radiation 
therapy. The purpose of this review is to collect the current evidence regarding application and 
limits of different therapeutic approaches for preventing postoperative recurrence of pterygium, 
giving insights and perspectives for better management of this disease. In the light of the current 
evidence, pterygium surgery cannot disregard wound coverage with conjunctival autografting 
or rotational flap combined with adjuvant treatments. The rotational flap technique is associ-
ated with shorter surgical time rates and prevents graft displacement and necrosis, given its 
vascular pedicle. Amniotic membrane may still be reserved in case of great conjunctival defects 
or insufficient conjunctiva. Repeated subconjunctival antivascular endothelial growth factor 
injections can be considered as an effective and safe adjuvant treatment. Moreover, manage-
ment of postoperative pain is crucial. Innovative treatment strategies will probably target dif-
ferent molecular pathways, considering recent findings regarding pterygium pathogenesis, to 
improve better understanding and develop universally shared guidelines. Great importance shall 
be dedicated to the identification of novel molecular biomarkers and favoring factors of recur-
rence, in order to achieve a customized surgical treatment for each patient and obtain maximal 
reduction of postoperative recurrence.
Keywords: pterygium, conjunctival autograft, rotational flap, amniotic membrane, adjuvant 
therapy, predicting factors
Introduction
Pterygium is an abnormal growth of epithelial and fibrovascular tissue invading the 
cornea across the limbus and can lead to impaired vision (due to excessive dimensions 
or induced astigmatism) or recurrent inflammation. Pterygium formation is thought 
to be the result of altered epithelial cell proliferation and altered vascularization.1–5 
However, the precise pathogenesis of this disease is still unclear.
Pathogenic factors related to pterygium formation include ultraviolet (UV) radia-
tion (as observed in numerous studies, probably through damage to DNA, proteins and 
lipids, both direct or induced by reactive oxygen species),6–10 viral infections (mainly 
herpes simplex virus, cytomegalovirus, and human papillomavirus),11–13 epigenetic 
aberrations, transition from epithelial to mesenchymal tissue,14 inflammatory and anti-
apoptotic mechanisms,15–18 neoangiogenic upregulation,2,19 stimulation of lymphangio-
genic response,20 deregulation of extracellular matrix modulators,21 growth factors,22–25 
recruitment of bone marrow-derived stem and progenitor cells,26,27 and modifications 
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in cholesterol metabolism.28 Moreover, Anguria et al reported 
that hereditary predisposition may be fundamental for the 
onset and persistence of pterygium.29
The main treatment for pterygium is surgical removal, 
which has to be taken into consideration in case of reduced 
visual acuity due to visual axis involvement, induced 
astigmatism, or frequent inflammation and discomfort. 
Surgical techniques include bare sclera excision, conjunctival 
autograft, conjunctival transpositional flap, and amniotic 
membrane grafting.30 However, pterygium surgery is con-
cerned by postoperative recurrence (whose rate can be up 
to 89% and its severity may vary according to the adopted 
approach and preoperative conditions) because fibrovascular 
growth may occur also with greater extension than its primary 
presentation.31
Predicting factors of recurrence are not fully understood, 
yet, but they probably depend on a multitude of patient-related 
(genetics, environment) and/or surgical factors.32 Among 
patient-related factors, ethnicity is considered a significant 
predisposing feature (Hispanics and dark-skinned individuals 
are the mostly affected).33 Other patients’ characteristics asso-
ciated with higher recurrence are young age, current active 
growth, preexisting disfiguration of lacrimal caruncle, ocular 
motility restriction, concurrent ocular surface inflammation, 
fibrogenic constitution, and family history.34
According to a grading system developed by Tan et al, 
a fleshy-like aspect of the pterygium is correlated with high 
recurrence rates, especially after bare sclera excision.35 
Greater vertical size of pterygium was also associated with 
a higher recurrence rate.34 Moreover, different biomarkers 
(which are involved in reduced inhibition of epithelial 
and fibroblastic proliferation) are associated with higher 
recurrence rate. For example, excessive levels of stromal 
cell-derived factor 1 (which promotes TGF-β expression) 
and angiogenin were observed in pterygium fibroblasts.36 
As of today, additional studies are needed to further evalu-
ate biomarkers before their application in clinical practice 
because histological and immunohistological features are still 
not sufficient to reliably predict recurrence predisposition.
Several adjuvant treatments have been proposed to reduce 
postoperative pterygium recurrence, including different anti-
metabolites, antiangiogenetic factors, radiations, as well as 
other novel materials and administration methods. The purpose 
of this review is to collect the current evidence regarding appli-
cation and limits of different therapeutic approach for prevent-
ing postoperative recurrence of pterygium, giving insights and 
perspectives for better management of this disease.
Surgical treatment
Bare sclera technique
The bare sclera technique is the first technique adopted for 
pterygium removal and is characterized by simple excision, 
allowing the scleral bed to re-epithelialize. However, this 
technique tends to favor postoperative pterygium prolif-
eration because small tissue residues may be left in the 
scleral bed, resulting in high recurrence rates (24%–89%).37 
A reduction of recurrence rates – as suggested by several 
authors – can be obtained by combination of excision with 
accurate Tenon and fibrotic tissue removal.32 Nevertheless, a 
recent research reported that bare sclera technique was associ-
ated with higher recurrence rates, which became lower when 
adjuvant treatments were used.37 The bare sclera technique 
can be easily performed with short surgical time (depending 
on pterygium size), and it is appealing for trainee surgeons, 
but it is currently rarely applied, given the high risk of 
recurrence. In fact, a meta-analysis of randomized controlled 
clinical trials comparing bare sclera technique and con-
junctival autograft demonstrated that the risk of recurrence 
following surgical treatment is significantly higher (ranging 
from 6 to 25 times) when no graft placement is performed.38 
In order to achieve better postsurgical outcomes and lesser 
recurrences, bare sclera technique must be associated with 
adjuvant treatments or alternative surgical techniques featur-
ing complete coverage of the conjunctival defect.
Conjunctival autograft
Conjunctival autografting was first described in 1985 by 
Kenyon et al. This technique involves the realization of a 
free autograft from nearby conjunctiva that will be applied 
over the exposed scleral bed once pterygium excision has 
been performed.39 This procedure is associated with lower 
recurrence rates when compared with the bare sclera excision 
alone, with more long-term efficacy. Even if recurrence rates 
after conjunctival autograft vary among different clinical 
studies, this technique is often considered to be the most 
effective method for pterygium treatment.
Syam et al reported a recurrence rate of 3.3% in their 
study, similar to the results obtained in a case series conducted 
by Bilge,40 while Koranyi et al, Fernandes et al, Ma et al, and 
Al Fayez reported 13.5%, 12.2%, 5.4%, and 8.3% recurrence 
rates, respectively.31,41–43 However, much higher recurrence 
rates have been reported (ranging from 31.3% to 33.3%), 
in case of recurrent pterygium excision.40 A novel technical 
variant named “pterygium extended removal followed by 
extended conjunctival transplantation” (P.E.R.F.E.C.T.) was 
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conducted in Australia, with reports of patients’ follow-up 
longer than 1 year and a recurrence rate of 1.6%.44
Although conjunctival autografting is effective in prevent-
ing pterygium recurrence, this technique requires technical 
expertise and extended operative time due to fixation of 
conjunctival autograft, especially when sutures are used. 
In fact, because of the need for graft fixation, the surgical 
time dedicated to conjunctival autograft can be longer than 
the one needed for simple bare sclera excision. Moreover, 
although rarely, the graft can be displaced or lost. Conjunc-
tival autografts can be fixated at the level of the scleral bed 
through different methods. Usually, sutures are associated 
with postoperative discomfort, chronic inflammation, and 
granuloma formation.45 Fibrin glue is an alternative, synthetic 
adhesive (prepared from a donor plasma), first described 
for pterygium surgery by Cohen and McDonald in 1993.46 
Koranyi et al confronted conjunctival autograft fixation using 
fibrin glue adhesive with suture-assisted fixation, reporting 
that fibrin glue had a 5.3% recurrence rate while suture-
assisted procedures were associated with a recurrence rate of 
13.5%.47 Fibrin glue fixation requires a shorter operation time, 
but its drawbacks include potential risk of infections, hyper-
sensitivity reactions, potential risk for dehiscence, and higher 
costs.48–50 Another fixation method that has been proposed is 
the in situ blood coagulum technique. This method has the 
advantages of eliminating the risk of transmitted infections 
and hypersensitivity reactions by using the patient’s own clot-
ting factors. Several studies have reported that recurrence rates 
of fibrin glue-assisted conjunctival autografting and in situ 
coagulum were similar; however, the use of autologous blood 
was associated with higher risk of graft displacement and 
retractions.51–53 In situ blood coagulum has similar recurrence 
rates and lesser postoperative discomfort when compared with 
suture-assisted procedures, but complications related to graft 
failure and graft retractions were still more common after the 
use of in situ blood coagulum, although the difference was 
not statistically significant.51 Kumar and Singh concluded that 
fibrin glue remains the most effective method for conjunctival 
autograft fixation in pterygium surgery with least surgical time 
and postoperative discomfort.45 The use of sutures is related 
to maximal surgical time and postoperative discomfort while 
providing better graft stability, but recurrence rates are lower 
with fibrin glue-assisted fixation.54 Cauterization is another 
surgical option, but it is still necessary to assess whether this 
method may be superior to fibrin glue. A clinical trial has 
been recently presented in order to evaluate the feasibility 
of this method in comparison with fibrin glue.55
Currently, graft edema, graft necrosis, graft displacement 
or loss, inclusion cysts, subconjunctival hematoma, Tenon’s 
granuloma, giant papillary conjunctivitis, corneal narrow-
ing, and Dellen ulcers have been reported to be the most 
common postoperative complications of primary pterygium 
surgery.56,57 Conjunctival granuloma (CG) is an uncommon 
complication of pterygium excision combined with a con-
junctival autograft. Mullins et al reported a prevalence of 2% 
of postoperative granulomas in their study.58 In a case series 
of 100 patients who underwent surgical treatment, a total of 
52 eyes developed CGs after pterygium surgery, of which 3 
were recurrent pterygium eyes.59 Zhang et al reported that the 
incidence of CGs in primary pterygium eyes was 1.3% and 
2.2% in the case of recurrent pterygia surgery.60 Common 
causes of granulation tissue development are foreign bod-
ies of several origins (suture material or filaments); laxly 
sutured conjunctival wounds with exposition of sclera and 
fascia tissue; uneven graft tissue edges; irregular conjunctival 
stitches; lack of local blood supply; inflammation, infection, 
or other minor factors (such as suture type and other foreign 
bodies).60,61 When conjunctival autograft is associated with an 
excessive use of mitomycin C, avascular scleral stromalysis 
may occur. However, even if recurrent cases with cicatricial 
strabismus may occur, conjunctival autograft in combination 
with mitomycin C presents low recurrence rates and must be 
taken into consideration.62
It has been shown that after a very long follow-up of almost 
two decades there are no significant differences regarding 
postoperative recurrences or complications when using upper 
or lower conjunctiva for grafting, even if larger studies are 
required in order to confirm these results.63,64 Moreover, it 
is possible that patients who underwent excision with lower 
flap reported less postoperative discomfort because the upper 
eyelid has a greater range of motion than lower eyelid, which 
might lead to a more intense inflammation, tear film instability, 
dry eye symptoms, and longer corneal epithelial healing time.64 
In the light of these considerations, conjunctival autograft in 
pterygium surgery can be associated with potential drawbacks. 
Closure of large defects is difficult, and the conjunctiva must 
be preserved for the possibility of glaucoma filtering surgery. 
Syam et al found that 36.66% of patients developed conjunc-
tival scarring at the site of the donor conjunctiva.65 For this 
reason, in case of patients who may benefit from glaucoma 
filtration surgery, it is more advisable to utilize inferior con-
junctival portions for autografting. In addition, it is not feasible 
to use this technique to cover wide ocular surface defects 
occurring in cases of large or double-headed pterygia.
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According to Paracha et al, recurrence rates of the con-
junctival autograft method were similar to those achieved 
when mitomycin was used in association with the bare sclera 
technique.66 Moreover, this technique has a lower recur-
rence rate when compared with the application of amniotic 
membrane or simple bare sclera excision.67,68 Finally, 
combination of conjunctival autograft with intraoperative 
mitomycin C proved to be more effective in reducing 
recurrence rates than cases in which the two techniques are 
separately applied.69,70
Amniotic membrane
Amniotic membrane is the innermost layer of the placenta 
(featuring a thick basement membrane and an avascular 
stromal matrix), which can be used as a graft with anti-
inflammatory and antifibrotic properties, capable of providing 
numerous growth factors, and promoting proliferation and 
differentiation of epithelial cells without the risk of immu-
nological reactions. Amniotic membrane stromal matrix is 
effective in suppressing the expression of TGF-β signaling 
and myofibroblast transformation in pterygium.71,72 Other 
studies have shown that amniotic membrane facilitates epi-
thelialization, maintains normal epithelial phenotype, and 
reduces inflammation, scarring, and vascularization.37,73,74 
Given these features, human amniotic membrane has been 
considered useful in several ophthalmic surgeries, includ-
ing pterygium and other conjunctival diseases.75 Typically, 
it must be placed over the bare sclera, with the basement 
membrane facing up and the stroma facing down. Fibrin 
glue may be also used to promote amniotic membrane graft 
fixation to the underlying sclera.
The application of amniotic membrane appears to be 
safe and effective, and it is associated with lower recurrence 
rates when compared with the bare sclera technique.76,77 
The reported recurrence rates with amniotic membrane 
graft vary between 3.8% and 40.9%. In a prospective study, 
Prabhasawat et al reported a recurrence rate of 10.9% after 
amniotic membrane apposition.73 Solomon et al subsequently 
modified the technique achieving a lower recurrence rate of 
3%.78 However, when compared with conjunctival autografts, 
amniotic membrane efficacy remains controversial.79
In fact, four randomized clinical trials examined ptery-
gium recurrence rates after amniotic membrane grafts 
compared with conjunctival autograft procedures. All 
four studies showed a lower pterygium recurrence rate in 
conjunctival or limbal autograft groups (P=0.05).80–83 Ma 
et al retrospectively evaluated the efficacy and safety of 
amniotic membrane compared with conjunctival autograft 
and topical 0.02% mitomycin C, after excision of primary 
pterygium, with no significant difference in recurrence rates 
among the groups under study.42 Given these considerations 
and comparable recurrence rates in the literature, pterygium 
excision associated with amniotic membrane is a less tedious 
and less time-consuming method, providing the possibility 
of conjunctival sparing, especially needed in case of future 
glaucoma surgery.
Inhibition of aberrant neovascularization, prevention 
of inflammation, and promotion of conjunctival re-
epithelialization are the main reasons for amniotic membrane 
effects in pterygium surgery.84–86 Conjunctival autografting 
may provide a source of conjunctival epithelium, whereas 
amniotic membrane seems to play a role in inhibiting the 
development of progenitor cells involved in pterygium 
recurrence.87 The procedural time of this technique can be 
potentially shorter, and it is technically easier to perform than 
conjunctival autografting. Even if results presented in the 
literature indicated similar visual acuity changes and epithelial 
healing with the amniotic membrane technique when com-
pared with conjunctival autografting, greater inflamma-
tion and higher recurrence rates were seen in the amniotic 
membrane group.88 Moreover, conjunctival autografting was 
more effective than amniotic membrane to prevent pterygium 
recurrence after a 6-month follow-up, especially in recurrent 
pterygia.79 Even so, amniotic membrane application may still 
be useful to cover large conjunctival defects after pterygium 
excision and to preserve conjunctiva in glaucomatous patients. 
Future studies should assess changes in patient-reported dis-
comfort and visual acuity, evaluating the effects of different 
surgical variations.
Amano et al showed a recurrence rate of 8.7% when 
intraoperative 0.04% mitomycin C was associated.89 This 
approach reduced mitomycin C dosage to avoid overspill 
to the entire ocular surface. Coupled with short exposure 
to mitomycin C, amniotic membrane can be considered as 
a feasible alternative for pterygium surgery, as shown in 
a case series by Rosen.90 Amniotic membrane grafts have 
been also used as an adjuvant procedure in combination with 
conjunctival autografting, in order to improve recurrence 
rates reduction. To date, the combined use of these two 
techniques has been reserved for large or severely inflamed 
lesions or in case of persistent recurrence.91 The safety and 
effectiveness of this combined method have been emphasized 
by several studies. Conjunctival autografting in combination 
with amniotic membrane further reduces recurrence rates, 
dry eye, and conjunctival inflammation compared with both 
techniques alone, with better clinical outcomes.92,93
In another study, the use of hyperdry amniotic membrane 
(HD-AM) has been evaluated in comparison with conjunctival 
Clinical Ophthalmology 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2351
Minimize pterygium recurrence rates
autograft.94 HD-AM is made with fresh human amniotic 
membrane using the hyperdrying method and returns to a 
layered structure after absorbing water. Okabe et al found that 
the structures of collagen fibers in the connective tissues were 
not destroyed in the hyperdry state and were more stable than 
cryopreserved amniotic membrane.95 Allen et al also showed 
that the biochemical composition of HD-AM, including 
the number of factors such as epidermal growth factor and 
TGF-β1, was similar to fresh amniotic membrane.96 HD-AM 
is useful in the covering of wide ocular surface defects such 
as in the case of large or double-headed pterygium. Moreover, 
management of HD-AM is simple and its use may lead to 
shorter operating times. It has been reported that recurrence 
rates in patients receiving HD-AM were significantly lower 
(5.06%) than recurrence rates in conjunctival autografting 
(20.97%; P=0.003).94
Conjunctival transpositional flap
Rotational conjunctival flaps have been carried out since 
1940s with different recurrence rates. McCoombes et al 
reported a 3.2% recurrence rate, whereas Alpay et al reported 
a recurrence rate of 33.33%.97,98 Bilge compared conjunctival 
transpositional flap with conjunctival autografting, evaluat-
ing its efficacy, safety, and operating time. Both procedures 
seemed to provide low recurrence rates, without severe 
complications. Conjunctival transpositional flap has less 
torsion effects on tissues and has better cosmetic results in 
an early and late postoperative period when compared with 
conjunctival autografting.40 This technique can be used as 
an acceptable method for pterygium surgery, especially in 
patients with insufficient conjunctiva.99 In general, conjunc-
tival transpositional flap is a more challenging surgery than 
conjunctival autografting, but once mastered, it needs less 
surgery time when compared with conjunctival autografting. 
It has been reported that the average surgery duration for 
both methods can be equal, at around 50 minutes, although 
it varies among different studies. This was attributed to 
the difficulty of separating the fibrovascular tissue from a 
small graft, the smaller size of the graft in relation with the 
bare sclera, and the need for more sutures to hold the graft 
in the transpositional method.99 Nevertheless, Dadeya et al 
have observed that the duration of transpositional flap is 
shorter than the autografting method by 20 minutes, saving 
a significant amount of surgical time with recurrence rates 
of 5.58% for rotational flap and 5.55% for autografting.100 
However, Wu et al reported that the recurrence rate after the 
transpositional flap technique was 35%.101 Jap et al used the 
rotational flap method when autografting was contraindicated 
and recorded a recurrent rate of 4% with an average follow-up 
of 12 months.102 Combination of transpositional conjunctival 
flap and intraoperative 0.02% mitomycin C for 5 minutes 
provided a recurrence rate of 3% after 1 year.103
All these findings suggest that the transpositional method 
is similar to conjunctival autografting in terms of recurrence 
rates, which become significantly lower when intraopera-
tive mitomycin C is applied, an effective separation of the 
fibrovascular tissue is performed, and corticosteroid eye 
drops are used for a longer postoperative time. Given that 
complications are more frequent in the autografting method, 
it is better to use this type of surgery when suitable or suf-
ficient conjunctiva for surgery is observed.100 Transpositional 
flap can be safely used when the conjunctival features do not 
allow conjunctival autografting, with similar recurrence rates 
and significantly shorter surgical time, even if more studies 
with a greater number of patients should be performed to 
get statistically significant results. In addition, conjunctival 
autografting may need peribulbar anesthesia and tractioning 
sutures, while it is nearly unnecessary for the transpositional 
flap technique.40 Also, in transpositional graft technique, there 
is no risk of graft loss and inversion, and the vessel structure 
is preserved, with better healing process and reduced risk 
of graft necrosis (Figure 1). However, transpositional flap 
cannot be taken into consideration in case of large pterygia 
in which a wider grafting is needed.
Adjuvant therapies
Mitomycin C
Mitomycin C, a substance isolated from Streptomyces 
caespitosus, is an antibiotic and antineoplastic drug that 
has been suggested as an adjuvant treatment for pterygium 
Figure 1 Postoperative results of a rotational flap, transposed from the inferior 
conjunctiva, with its vascular pedicle.
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surgery in the early 1960s.104 Positive outcomes have 
been reported after an intraoperative application of 0.02% 
mitomycin C. In fact, recurrence after mitomycin C use in 
primary pterygium has been reported to be as low as 7%, 
while rates after recurrent pterygia were reduced to 9%.105 
The association of 5-minute application of 0.02% mitomycin 
C with bare sclera excision showed to reduce the recurrence 
rate to 5%.106 Moreover, no substantial differences have 
been observed between postoperative 0.02% mitomycin C 
for 5 days or intraoperative mitomycin C at different dos-
ages when combined with rotational conjunctival flap.107–112 
However, it has been shown that conjunctival autografting 
is associated with significantly lower recurrence rates when 
compared with excision combined with intraoperative 
mitomycin C.69,113 Nonetheless, two studies reported that the 
combination of conjunctival autograft with mitomycin C, 
regardless of the application dosage or method, resulted in 
significantly lower pterygium recurrence.69,114 Moreover, 
Cardillo et al have reported recurrence rates ranging from 
4% to 6% with mitomycin C of 0.02% and 0.04%. Given 
the similar efficacy, it is recommended to use intraoperative 
mitomycin C at the lowest dose.113 The most commonly 
used concentration of mitomycin C is 0.02% (0.2 mg/mL), 
and the most common application time length is 3 minutes. 
However, further studies are still needed to determine the 
optimal concentration and exposure duration.37
Several randomized controlled clinical trials compared 
recurrence rates using various protocols that incorporated 
intraoperative or postoperative mitomycin C with different 
exposure times. Studies regarding primary pterygia alone 
or combined with recurrent pterygia reported no significant 
differences in recurrence rates in case of intraoperative or 
postoperative mitomycin C.115–117 Currently, there are no 
data suggesting whether intraoperative or postoperative 
mitomycin C is more efficacious when combined with 
conjunctival autograft surgery.
Common complications after mitomycin C application 
are usually limited to photophobia, postoperative irritation, 
and ocular discomfort with increased tears, especially if 
used at low dosages.118 However, severe complication can 
still occur, even after several months from initial treat-
ment. Such adverse events include cataract, symblepharon, 
anterior uveitis, iritis, scleral thinning or necrosis, corneal 
opacification and ulceration, prolonged pain, and persistent 
conjunctival and scleral defects.37 High doses and patients’ 
predisposition (eg, dry eye, ichthyosis, acne rosacea) are 
probably the main reason for mitomycin C-related adverse 
events.32 Hayasaka et al reported late complications featuring 
calcified plaques at the level of the excision site. When these 
plaques were removed, scleral thinning was observed, with 
the need for additional patching grafts in some cases.105 
Finally, Dougherty et al described a case of severe corneo-
scleral melting in a patient receiving application of 0.02% 
mitomycin C for 3 minutes followed by closure with a con-
junctival rotational flap.119
5-Fluorouracil (5-FU)
5-FU is an antimetabolite first synthesized in 1957 by 
Dushinsky et al,120 with inhibiting effects on the prolif-
eration of corneal epithelial cells and fibroblasts located in 
conjunctiva and Tenon’s capsule. 5-FU has been used as an 
adjuvant in pterygium surgery with recurrence rates ranging 
from 11.4% to 60.0% after bare sclera technique.121 Accord-
ing to a series of 125 eyes receiving intraoperative 5-FU (at 
a dose of 25 mg/mL), pterygia recurred in 36%.122 Higher 
doses of 5-FU (50 mg/mL) lead to a recurrence decrease at 
around 11%, with no statistically significant advantages when 
compared with conjunctival autografting alone.121 Although 
there is little evidence in the literature to encourage a routinely 
5-FU use for this surgery, this adjuvant treatment appears to 
maintain a role in treating recurrent pterygia.123–125 In fact, 
Prabhasawat et al reported recurrence rates of 7.7% when 
5-FU was used for impending recurrent pterygium.73
Only minor or temporary adverse events have been 
reported after 5-FU use in pterygium surgery.32 However, 
a case of cicatricial ectropion after topical 5-FU and a case 
of punctal–canalicular stenosis after systemic administra-
tion have been described.126,127 Adverse events after 5-FU 
application are more commonly reported in its employment 
for glaucoma surgery, including persistent epithelial defects, 
spontaneous bleb rupture, and bacterial ulcerations. However, 
5-FU doses used in these cases are five to ten times higher 
than those suggested for pterygium surgery (10/20 mg). 
Because toxicity is still possible even at lower doses, the 
use of 5-FU is not recommended in patients with a history 
of corneal diseases.128,129
Radiation
The use of radiotherapy as an adjuvant treatment for 
pterygium has been described since 1912.130 Since 1950, the 
radioactive material used for pterygium treatment through 
irradiation has been strontium-90 (88Sr). This element seems 
suitable for the treatment of ocular surface diseases because 
it emits β-rays whose energy decrease rapidly as they 
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penetrate in the underlying tissues (dropping off to 41% at 
1 mm depth, 19% at 2 mm, 9% at 3 mm, and 1% at 5 mm), 
preventing damage to deeper structures.131 Currently, there 
exists a wide variety of dose fractionation schemes, rang-
ing from 20 Grays (Gy) in single fraction in the immediate 
postoperative period to 60 Gy in 6 weekly fractions or 24–30 
Gy in 3 weekly fractions.132–134 Positive outcomes were also 
proven in case of immediate postoperative radiotherapy of 
25 Gy in a single fraction, after excision with bare sclera 
technique (6.82% recurrence rate).132 Brenner and Merriam 
implied that fractionation rather than single dose gives an 
increased therapeutic ratio between absence of recurrences 
and late side effects.135 Nonetheless, as supported by the 
North Florida Pterygium Study Group and other authors, 
radiotherapy gives best results when started within 24 hours 
of complete excision.134
Adverse events following radiotherapy include ocular 
burning, foreign body sensation, photophobia, conjunctival 
scarring, corneal opacities, cataracts, grauloma formation, 
and scleral atrophy. Severe late adverse events that may occur 
years after surgery are represented by bacterial corneoscleri-
tis, scleral ulceration, and symblepharon.136–139 However, 
as of today, there is still no definitive consensus between 
single dose vs total dose. Moreover, the most effective time 
of exposure needs to be further assessed.
Antivascular endothelial growth factor 
(anti-veGF)
Khalfaoui et al found that VEGF is overexpressed in recurrent 
pterygium and suggested an important role of angiogenesis 
and neovascularization in pterygium recurrence.140 The first 
study to report a case of subconjunctival injection of beva-
cizumab in primary pterygium was conducted by Teng et al. 
A subconjunctival injection of bevacizumab was performed 
into an inflamed pterygium at the level of the limbus, with 
rapid regression of neovascularization signs, and inflam-
mation, although the effects were only short term.141 This 
transient effect is probably related to a limited bioavailability 
in a framework of continuous VEGF expression. An inten-
sive high-dose anti-VEGF therapy with ziv-aflibercept can 
lead to resolution of inflammation and new vessel growth 
in inflamed pterygia, but current evidence does not support 
intralesional VEGF antagonists in the surgical management 
of noninflamed pterygia.142
Shenasi et al, in their study evaluating subconjunctival 
bevacizumab injection immediately after pterygium excision, 
found that the recurrence rate was lower in patients receiving 
the adjuvant treatment.143 Razeghinejad and Banifatemi 
reported that subconjunctival bevacizumab injected immedi-
ately after rotational conjunctival flap and 4 days after surgery 
was efficient in preventing pterygia recurrence, even if the 
difference with the control group failed to reach a statistically 
significant level.144 Shahin et al found that a subconjunctival 
injection of 1.25 mg/0.05 mL of bevacizumab at the end of 
the surgery did not result in a statistically significant differ-
ence in the recurrence rates.145
Even if a single postoperative administration of subcon-
junctival bevacizumab is well tolerated and decreases the 
number and caliber of corneal blood vessels, this favorable 
effect is incomplete and temporary.146 Repeated injec-
tions in the first year after surgery may help prevent the 
high recurrence rate; however, side effects of multiple or 
increased doses must be addressed, and further evaluations 
are needed to be prove bevacizumab as a good adjuvant. 
In fact, considering its high costs, bevacizumab has not 
presented fully satisfactory results. In a previous study, we 
evaluated the application of subconjunctival bevacizumab 
injections at the dosage of 2.5 mg/0.1 mL, before and after 
surgical pterygium excision with bare sclera technique 
(1 week before and 15 days after surgery). It was the only 
study with this particular injection timing, proving that 
this repeated modality may be useful in preventing lesion 
recurrence after bare scleral procedures and that it can 
lead to more satisfactory benefit–cost ratio. Furthermore, 
bevacizumab subconjunctival administration is well toler-
ated and may represent a safer alternative when compared 
with other surgical techniques and adjunctive drugs.147 
Finally, a recent meta-analysis by Sun et al confirmed a 
statistically significant effect of bevacizumab in preventing 
primary pterygium recurrence, without significant increase 
in adverse reactions.148
Preoperative subpterygium-combined injection of beva-
cizumab and mitomycin C is safe and effective in reducing 
the postoperative recurrence of primary pterygium, espe-
cially if applied 1 month before surgery. A study evaluating 
histological and immunohistological changes reported a 
decreased fibrovascular activity and degeneration of the 
extracellular matrix and nerve axons. Moreover, combination 
of mitomycin C and bevacizumab led to a significant decrease 
in CD31-positive cells, with low levels of inflammatory 
cellular infiltration, fibroblasts, and goblet cells, in associa-
tion with a significant increase in collagen fibers. This could 
be secondary to the combined anti-VEGF action of beva-
cizumab and the antifibroblastic activity of mitomycin C.149
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Topical cyclosporine A (CsA)
CsA is an anti-inflammatory and immunosuppressive drug, 
which can help to significantly reduce pterygium recurrence 
when used in the postoperative time.150,151 Ibáñez et al used 
adjuvant CsA at a 0.10% concentration, which differed 
from other studies that used CsA at a 0.05% concentra-
tion with no significant differences.152 Moreover, adjuvant 
use of CsA in the treatment of pterygium was superior 
when compared with patients receiving only excisional 
surgery.151,153,154
In the study by Aydin et al, only one case of recurrence 
occurred in the CsA group after conjunctival autografting, 
with a recurrence rate five times lower than the control 
group.153 However, because of the small sample size, the 
study failed to reach statistical significance. Similarly, in 
the study by Ibáñez et al, the recurrence rate was two times 
higher in the control group than in the CsA group.152
It is possible that surgical techniques as conjunctival 
autograft or conjunctival flap rotation could themselves 
decrease the incidence of pterygium recurrence, regardless 
of the adjuvant use of CsA. Thus, additional studies with 
larger sample sizes and longer follow-up are needed in 
order to draw more definitive conclusions. Possible mecha-
nisms explaining the adjuvant use of CsA are related to the 
higher expression of IL-6 and IL-8 in pterygia epithelium 
leading to angiogenesis increase through VEGF.16,155,156 
Similarly, T-lymphocyte-mediated cellular immunity seems 
to play a key role in pterygium pathogenesis. Moreover, 
Lin et al showed that lymphatic microvessel density was 
a predictive factor for pterygium recurrence.157,158 CsA can 
selectively suppress T-lymphocytes, which can produce 
inflammatory cytokines and mediators.159 In addition, 
CsA can also inhibit the angiogenesis triggered by VEGF. 
Therefore, inhibition of both these pathways provided 
by CsA might be an effective method for preventing 
postoperative recurrence.
Adjuvant use of CsA is relatively safe in comparison 
with other adjuvant treatment, except in the case of preexist-
ing scleral thinning. Nevertheless, CsA administration can 
still be considered a well-tolerated adjuvant substance for 
pterygium treatment. However, the current limited evidence 
can only suggest that CsA is useful to significantly reduce 
recurrence rates when compared with simple pterygium exci-
sion, whereas the adjuvant use of CsA may not reduce the risk 
of pterygium recurrence when combined with conjunctival 
autografting or rotational flap.151
Clinical perspectives
Key features of surgical techniques and adjuvant treatments 
are summarized in Tables 1 and 2, respectively. Meticulous 
excision of pterygium stromal tissue is the first step that 
must be performed to achieve favorable surgical outcomes 
Table 1 Summary of main characteristics of different surgical techniques for pterygium excision
Technique Advantages Drawbacks
Bare sclera technique •	 easy to perform
•	 Short surgical time
•	 High recurrence rates
•	 Possible discomfort and pain (related to pterygium  
extension)
Conjunctival autograft •	 Low recurrence rates
•	 Easy to perform (in comparison with transpositional flap)
•	 Good cosmetic results
•	 Long surgical time (especially in suture-assisted fixation)
•	 Possible discomfort and pain (especially in suture-assisted  
fixation)
•	 Cannot be applied in patients with insufficient conjunctiva
•	 Risk of graft loss/displacement (sutureless fixation)
•	 Possible conjunctival cicatrization
•	 Difficulty in covering of large defects
Amniotic membrane •	 easier to perform (in comparison with conjunctival  
autografting)
•	 Useful to cover large defects
•	 Conjunctival sparing
•	 Short surgical time
•	 Can be applied in patients with insufficient conjunctiva
•	 Higher recurrence rates (in comparison with conjunctival  
autografting)
•	 Risk of graft loss/displacement (sutureless fixation)
•	 Possible discomfort and pain (suture-assisted fixation)
Conjunctival  
transpositional flap
•	 Low recurrence rates
•	 Low risk of graft loss or necrosis
•	 Better graft healing due to vascular pedicle
•	 Short surgical time
•	 Better postoperative cosmetic results (in comparison  
with conjunctival autografting)
•	 Can be applied in patients with insufficient conjunctiva
•	 Challenging technique (in comparison with conjunctival  
autografting)
•	 Difficulty in covering of large defects
•	 Possible discomfort and pain (suture-assisted fixation)
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Table 2 Summary of characteristics of different adjuvant treatments in pterygium surgery
Adjuvant treatment Advantages Drawbacks
Topical mitomycin C •	 Significant recurrence rate reduction •	 Low tolerability
•	 Risk of severe toxicity (eg, corneoscleral necrosis)
•	 Cannot be applied in case of thin sclera or preexisting corneal disease
Radiation •	 Significant recurrence rate reduction •	 No unified fractioning schemes
•	 Corneoscleral toxicity
•	 Possible late-onset toxicity (eg, infections and scleral ulceration)
Subconjunctival anti-veGF •	 Significant recurrence rate reduction
•	 Good tolerability
•	 Possible repeated injections
•	 High costs
•	 Transient effect
•	 No unified injection timing
Topical 5-fluorouracil •	 Minor toxicity in pterygium surgery
•	 Useful in recurrent pterygium
•	 Controversial efficacy
•	 Limited evidence for pterygium surgery
•	 No significant recurrence reduction when compared with simple surgery 
with conjunctival graft
•	 Cannot be applied in case of thin sclera or preexisting corneal disease
Topical cyclosporine A •	 Mechanism of action on multiple 
pathological processes
•	 Good tolerability
•	 High costs
•	 Limited evidence for pterygium surgery
•	 Cannot be applied in case of thin sclera
Abbreviation: veGF, vascular endothelial growth factor.
because the presence of fibroblasts is probably related to 
postoperative recurrence. However, this is not sufficient to 
prevent recurrence events. In order to minimize the risk of 
postoperative recurrence, it is necessary to perform a com-
plete fibroblast ablation at the level of the surgical wound 
through accurate removal of subconjunctival fibrovascular 
tissue. In addition, to promote rapid epithelialization, the 
bare scleral area should always be covered using a conjunc-
tival rotational flap, amniotic membrane, or a conjunctival 
autograft. In fact, bare sclera technique is characterized by 
high recurrence rates ranging from 33% to 88%.35
Moreover, a residual large defect after excision induces 
severe pain leading to wound hypertrophy and higher risk of 
recurrence, according to our and other authors’ experience.160 
It has been reported that neuropeptides involved in pain 
sensitivity, such as substance P, stimulates chemotaxis of 
injury-inducible stromal-like cells from the bone marrow to 
the site of injury.161 For these reasons, techniques leading to 
high perioperative pain should be avoided if possible. In addi-
tion, epithelial wound healing should be promoted and accel-
erated in order to prevent prolonged stromal overgrowth that 
may occur when the overlying epithelium (which provides 
inhibition of stromal proliferation through contact) is absent. 
Postoperative pain management is crucial in reducing the risk 
of recurrence and should be performed through either ban-
dage patching or therapeutic contact lenses (TCLs). Despite 
the fact that bandage patching may interfere with visual field 
(thus contraindicated in case of monocular vision), it has 
been reported that this method procures better pain relief and 
sleep quality in the first 24 hours after pterygium excision 
when compared with TCLs.162 For this reason, tight bandage 
patching should be preferred over contact lenses if no con-
traindications to ocular occlusion are observed. TCLs can 
still be applied in case of persistent pain or corneal defects 
after the first postoperative day. Anyways, both methods 
proved to be efficient in controlling postoperative pain and 
favoring corneal reepithelization.163–165 Anti-inflammatory 
eye drops, such as corticosteroids and NSAID, and artificial 
tears represent commonly used molecules for controlling pain 
and favoring corneal healing after pterygium surgery. It has 
been observed that nepafenac 0.1% eye drops administered 
thrice a day for 3 days (in association with postoperative 
therapy with topical ciprofloxacin, fluorometholone, and 
artificial tears) provided a significant pain reduction when 
compared with placebo after pterygium excision with autolo-
gous conjunctival graft.166 An alternative treatment for rapid 
corneal epithelial healing and pain reduction after pterygium 
surgery is represented by autologous serum eye drops, which 
led to favorable results, as reported in a study by Sul et al.167 
However, the evidence of autologous serum eye drops in 
pterygium surgery is currently limited. In addition, systemic 
analgesic drugs should be considered in the management of 
postoperative pain, especially if intense or persistent despite 
adequate topical treatment.
Immediate coverage of large defects with conjunc-
tival autograft, rotational flap, or amniotic membrane is 
recommended. Healthy conjunctival tissue should be pre-
served if possible, especially in case of patients who may 
require surgery for glaucoma. As of today, conjunctival 
autografting is considered the most effective technique 
for pterygium treatment and proved to provide better out-
comes with respect to amniotic membrane transplantation. 
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Moreover, conjunctival autografting operating time can be 
importantly reduced, thanks to sutureless fixating techniques. 
According to the literature, amniotic membrane transplanta-
tion can still be reserved in case of unhealthy or insufficient 
conjunctival tissue. In our experience, in case of recurrence 
after conjunctival rotational flap technique, it is advisable to 
apply a conjunctival or amniotic membrane patch associated 
with long-lasting treatment with corticosteroid eye drops in 
order to reduce postsurgical flogosis. Superior or inferior 
conjunctival tissue did not prove to provide better results 
when compared with each other.
Several adjuvant options to reduce the proliferative activ-
ity of stromal fibroblasts during the postoperative recovery 
phase have been proposed. Fonseca et al suggested that 
bare sclera excision + β therapy 25 Gy in single dose, bare 
sclera technique + mitomycin C 0.02%, and conjunctival 
autograft + cyclosporine 0.05% eye drops are the best 
strategies to prevent recurrence after pterygium surgery.168 
However, randomized clinical trials to evaluate efficacy 
of adjuvant therapies for pterygium are relatively few and 
with small sample size. In the light of the current evidence, 
mitomycin C, β-radiotherapy, and bevacizumab were signifi-
cantly more effective than placebo for reducing recurrence 
following pterygium excision, with mitomycin C having the 
higher efficacy.118,169–173 Although bevacizumab ranked higher 
than β-radiotherapy for its efficacy, this difference was not 
statistically significant. However, bevacizumab is associ-
ated with less severe adverse events when compared with 
mitomycin C or radiation therapy; hence, repeated injections 
(which are needed to avoid the transient effects of anti-VEGF 
drugs) are safe and possible. Topical postoperative CsA gives 
appealing hopes for adjuvant therapy, but current evidence 
is still poor to evaluate its safety and efficacy in pterygium 
surgery. 5-FU did not show a statistically significant efficacy 
in preventing postoperative recurrence.
As of today, optimal dose, duration, and administration 
protocol for adjuvant treatments are still not fully defined. With 
regard to radiotherapy, the commonly used dose is 25 Gy with 
bare sclera technique, which is decreased to 10 Gy when com-
bined with conjunctival autografting.174 Administration and 
dose of 5-FU were consistent among trials; however, duration 
of administration varied from 3 to 5 minutes. Bevacizumab 
dosage ranged from 1.25 to 7.5 mg in different studies, and 
its administration approach can be manifold among different 
studies.174 The most common way of bevacizumab adminis-
tration is subconjunctival at the time of surgery, associated 
with pre- or postoperative injections. We have reported that 
recurrence after bare sclera technique was reduced with 
both pre- and postoperative subconjunctival injections of 
bevacizumab and that this administration protocol is safe 
and feasible.147 Administration protocols of mitomycin C 
are inconsistent as well, with different dose, durations, and 
approaches. Adjuvant treatments still need standardization 
regarding dosage, time, and ways of administration because 
no definitive recommendations or guidelines are being pro-
duced. Another issue that must be taken into consideration 
is the side effects associated with adjuvant therapies, which 
alter the benefit–risk ratio. Therefore, the detection of patients 
who will benefit from adjuvant treatments is most relevant in 
the preoperative setting and risk factors for recurrence must 
be addressed. Reports showed that 50% of recurrences might 
occur within 4 months and 97% might occur within 12 months. 
Thus, follow-up of at least 1 year is appropriate.
Some studies reported that age, race, morphology, and 
increased inflammation after surgery are related to a greater 
risk of recurrence.34,175–180 Therefore, accurate collection of 
patients’ clinical information is fundamental to better predict 
the recurrence risk. However, actual assessment tools for 
routine clinical practice have not yet been developed for this 
disease. In order to find out reliable strategies for pterygium 
treatment, better understanding of molecular mechanisms 
involved in its pathogenesis is necessary. Several molecular 
pathways have been evaluated, and different biomarkers have 
been proposed. It is known that pterygium features altered 
proliferation of basal epithelial cells and neovascularization, 
with invasion of corneal epithelium. UV radiation, together 
with epigenetic aberrations, is strongly related to pterygium 
development and progression. However, because viral infec-
tions have been reported as a potential factor for pterygium 
pathogenesis, deeper understanding of their role may be 
crucial in the detection of subjects at risk of recurrence.14 
Pterygium fibrovascular redness has been proposed as a 
novel parameter for pterygium grading. In fact, an automated 
redness analysis proposed by Hilmi et al showed a signifi-
cant correlation with visual acuity and contrast sensitivity 
reduction, suggesting that pterygium morphology must be 
considered for the evaluation of clinical decisions and post-
operative recurrence prediction.181
Several growth factors and cytokines involved in 
angiogenesis and lymphangiogenesis, and many different 
proteinases as well, are related to pterygium development 
and persistence. Another promising field of research for 
pterygium pathogenesis is represented by modifications of 
cholesterol metabolism, even if further studies are needed.14 
Transition from epithelial to mesenchymal cells in pterygium 
has suggested that this pathology shares molecular basis with 
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tumors. In fact, molecular pathways involved in increased 
proliferative activity (Ki-67, proliferation cell nuclear 
antigen, and erythropoietin), inhibition of apoptosis (Bcl-2 
and p53), and malignancy (Hsp90) are overexpressed in 
the epithelial pterygium cells when compared with normal 
conjunctiva.182–184 In addition, abnormal methylation of 
genes related to extracellular matrix modulation 2, tumor 
suppression (p16), and cell adhesion (TGM-2 and CD24) has 
been correlated to pterygium invasiveness and uncontrolled 
proliferation.185,186 Oxidative stress caused by UV radiation 
may be responsible for these abnormal methylation patterns, 
although not confirmed yet.
Several studies have demonstrated a significant improve-
ment in induced astigmatism after pterygium surgery.187–192 
Kheirkhah et al evaluated corneal astigmatism with a 
Scheimpflug imaging system, concluding that pterygium 
surgery was associated with significant changes in curvature 
of front and back corneal surfaces, especially in case of 
advanced pterygia.193 However, it has been observed that no 
surgical technique or fixating method was superior in terms of 
postoperative astigmatism changes.194 Pterygium, especially 
with large size, is correlated with optical aberrations, and sev-
eral studies have demonstrated that surgery with conjunctival 
autograft leads to significant improvements in corneal wave 
front aberrations (including high-order aberrations, trefoil, and 
coma), visual acuity, refractive errors, and different corneal 
topographic values.195–198 However, there are no comparison 
studies regarding optical aberration modifications after adju-
vant techniques different from conjunctival autografting.
Conclusion
Bare sclera technique is associated with worst outcomes, 
with higher recurrence risk. Pterygium surgery cannot dis-
regard wound coverage with conjunctival autografting or 
rotational flap combined with adjuvant treatments. According 
to our experience, the conjunctival rotational flap technique 
is associated with low recurrence rates and the vascular 
pedicle prevents graft displacement and necrosis. Despite 
their high cost, subconjunctival anti-VEGF injections (which 
can be performed before and after surgery) are a safe and 
efficient adjuvant treatment. However, future treatment 
strategies will probably target multiple pathways, taking 
into consideration the novel findings related to pathogenesis. 
Additional studies should consider recurrence rates in accor-
dance with geographic regions and long-term follow-ups 
to improve the understanding of pterygium treatment and 
develop universal guidelines. Great importance should be 
dedicated to the identification of novel molecular biomarkers 
of recurrence, in order to perform a customized surgical 
treatment for each patient and achieve maximal reduction of 
postoperative recurrence.
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